The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis
Yıl: 2021 Cilt: 27 Sayı: 2 Sayfa Aralığı: 133 - 139 Metin Dili: İngilizce DOI: 10.4274/tnd.2021.50329 İndeks Tarihi: 19-01-2022
The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis
Öz: Objective: Multiple sclerosis (MS) is a condition involving central nervous system invasion by immune-inflammatory cells. In this study, we investigated whether the systemic immune-inflammation index (SII) could predict disability cross-sectionally as a novel and useful tool in patients with MS. Materials and Methods: We retrospectively reviewed the medical records of 148 patients with MS and 84 healthy controls and gathered the relevant clinicallaboratory data. SII in the remission period was calculated using the equation (SII: Platelet count x neutrophil count/lymphocyte count). The odds ratio of each immune formulation index was calculated by logistic regression analysis. In addition, the cut-off value, sensitivity and specificity of SII were calculated using receiver operating characteristics curve analysis. Results: Age and sex characteristics were similar in the groups (p>0.05). All values obtained through complete blood counts were significantly lower in the patient group (p<0.05). It was seen that the Expanded Disability Status scale (EDSS) was particularly correlated with the neutrophil-lymphocyte ratio and SII (p=0.013, 0.037 rho: 0.225, 0.192, respectively). In addition, we found that SII [ExpB: 0.015, 95% confidence interval: (0.999-1.003); p<0.001] was associated with disease disability in the MS groups formed according to EDSS. Furthermore, the cut-off value for SII was 254.51 x103/ul with 37% specificity and 95.5% sensitivity. Conclusion: A high SII may be a promising prognostic marker that is an easily available, inexpensive, and effective tool for predicting the disease disability in MS. Future studies with a larger number of patients may confirm our results.
Anahtar Kelime: MS Hastalarında Engellilik İçin Yeni Bir Prognostik Belirteç Olarak Sistemik İmmün-enflamasyon İndeksinin Prediktif Değeri
Öz: Amaç: Multipl skleroz (MS) hastalığı doğuştan gelen ve kazanılmış immün sistem disfonksiyonunun özürlülük artışına yol açtığı santral sinir sistemi istilası durumudur. Biz bu çalışmada, MS hastalarında yeni ve kullanışlı bir araç olarak sistemik immün-enflamasyon indeksinin (SII) kesitsel olarak disabiliteyi tahmin edip edemeyeceğini araştırdık. Gereç ve Yöntem: Yüz kırk sekiz MS hastasının tıbbi kayıtlarını retrospektif olarak inceledik ve klinik-laboratuvar verilerini elde ettik. Atak dışı dönemdeki SII, (SII: Trombosit sayısı x nötrofil sayısı/lenfosit sayısı) denklemi ile hesaplandı. Elde edilen hemogram parametreleri sağlıklı kontrol grubu ile karşılaştırıldı. Expanded Disability Status scale (EDSS) >3 ve EDSS <3 olarak oluşturan gruplarda lojistik regresyon analizi ile immün parametrelerin olasılık oranları hesaplandı. Ayrıca SII’nın eşik değeri, duyarlılık ve özgüllükleri alıcı işletim karakteristiği analizi ile elde edildi. Bulgular: Hastaların ortanca yaşı 39, kontrol grubunun 36 olup kadın erkek oranı gruplar arasında benzerdi (p>0,05). Hasta grubunda trombosit, nötrofil ve monositin lenfosite oranlanması ile edilen tüm değerler anlamlı düşüktü (p<0,05). EDSS’nin özellikle nötrofil-lenfosit oranı ve SII ile korele olduğu görüldü (p=0,013, 0,037 rho: 0,225, 0,192). Ayrıca EDSS’ye göre oluşturulan MS gruplarında SII’nin (p=0,000 ExpB: 0,015, güven aralığı: %95 0,999-1,003) hastalık disabilitesi ile ilişkili olduğunu saptadık. Ayrıca SII için cut-off değeri %37 spesifite ve %95,5 sensitiflik oranı ile 254,51 x103/ul olarak bulundu. Sonuç: Yüksek bir SII, MS’de hastalık disabilitesi göstergesi olarak umut vadeden elde edilmesi kolay, ucuz ve etkili prognostik bir belirteç olabilir. Daha uzun takipli büyük ölçekli çalışmalara ihtiyaç vardır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. D’Amico E, Zanghì A, Romano A, et al. The neutrophil-to-lymphocyte ratio is related to disease activity in relapsing remitting multiple sclerosis. Cells 2019;8:1114.
- 2. D’Amico E, Zanghì A, Gastaldi M, et al. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmun Rev 2019;18:665-672.
- 3. Losy J. Is MS an inflammatory or primary degenerative disease? J Neural Transm 2013;120:1459-1462.
- 4. Rumble JM, Huber AK, Krishnamoorthy G, et al. Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med 2015;212:23-35.
- 5. Hemond CC, Glanz BI, Bakshi R, Chitnis T, Healy BC. The neutrophilto- lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol 2019;19:23.
- 6. Dziedzic A, Bijak M. Interactions between platelets and leukocytes in pathogenesis of multiple sclerosis. Adv Clin Exp Med 2019;28:277-285.
- 7. Langer HF, Choi EY, Zhou H, et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 2012;110:1202- 1210.
- 8. Hong X, Cui B, Wang M, et al. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 2015;236:297-304.
- 9. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014;20:6212-6222.
- 10. Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immuneinflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget 2017;8:75381-75388.
- 11. Lu Z, Yan W, Liang J, et al. Nomogram based on systemic immuneinflammation index to predict survival of tongue cancer patients Who Underwent Cervical Dissection. Front Oncol 2020;10:341.
- 12. Chen L, Kong X, Wang Z, et al. Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator. Cancer Manag Res 2020;12:1543-1567.
- 13. Ozbek E, Besiroglu H, Ozer K, Horsanali MO, Gorgel SN. Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma. Int Urol Nephrol 2020;52:1455-1463.
- 14. Wang D, Hu X, Xiao L, et al. Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. J Gastrointest Surg 2021;25:421-427.
- 15. Kim Y, Choi H, Jung SM, et al. Systemic immune-inflammation index could estimate the cross-sectional high activity and the poor outcomes in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton) 2019;24:711-717.
- 16. Noseworthy J, Vandervoort M, Wong C, Ebers G. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990;40:971-975.
- 17. Şen S. Neurostatus and EDSS calculation with Cases. Noro Psikiyatr Ars 2018;55(Suppl 1):S80-S83.
- 18. Uitdehaag BM. Disability outcome measures in phase III clinical trials in multiple sclerosis. CNS Drugs 2018;32:543-558.
- 19. Goodin DS, Reder AT, Bermel RA, et al. Relapses in multiple sclerosis: relationship to disability. Mult Scler Relat Disord 2016;6:10-20.
- 20. van Munster CE, Uitdehaag BM. Outcome measures in clinical trials for multiple Sclerosis. CNS Drugs 2017;31:217-236.
- 21. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162-173.
- 22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
- 23. Çinar BP, Yorgun YG. What we learned from the history of multiple sclerosis measurement: expanded disability status scale. Noro Psikiyatr Ars 2018; 55(Suppl 1): S69-S75.
- 24. Wachowicz B, Morel A, Miller E, Saluk J. The physiology of blood platelets and changes of their biological activities in multiple sclerosis. Acta Neurobiol Exp 2016;76:269-281.
- 25. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007;7:161-167.
- 26. Zhang Y, Lin S, Yang X, Wang R, Luo L. Prognostic value of pretreatment systemic immune-inflammation index in patients with gastrointestinal cancers. J Cell Physiol 2019;234:5555-5563.
- 27. Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg 2019;270:139-146.
- 28. Shi H, Jiang Y, Cao H, et al. Nomogram based on systemic immuneinflammation index to predict overall survival in gastric cancer patients. Dis Markers 2018;2018:1787424.
- 29. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 2004;10:4895-4900.
- 30. Yilmaz A, Mirili C, Bilici M, Tekin SB. A novel predictor in patients with gastrointestinal stromal tumors: Systemic immune-inflammation index (SII). J BUON 2019;24:2127-2135.
- 31. Wang B, Huang Y, Lin T. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 2020;99:e18571.
- 32. Chovanec M, Cierna Z, Miskovska V, et al. Systemic immune-inflammation index in germ-cell tumours. Br J Cancer 2018;118:831-838.
- 33. Casserly CS, Nantes JC, Hawkins RFW, Vallieres L. Neutrophil perversion in demyelinating autoimmune diseases: Mechanisms to medicine. Autoimmun Rev 2017;16:294-307.
- 34. Naegele M, Tillack K, Reinhardt S, et al. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmun 2012;242:60-71.
- 35. Keller CW, Lünemann JD. Autophagy and autophagy-related proteins in CNS autoimmunity. Front Immun 2017;8:165.
- 36. Alirezaei M, Fox HS, Flynn CT, et al. Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis. Autophagy 2009;5:152- 158.
| APA | Sacmacı H, AKTÜRK T, TANIK N (2021). The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. , 133 - 139. 10.4274/tnd.2021.50329 |
| Chicago | Sacmacı Hikmet,AKTÜRK TÜLİN,TANIK NERMİN The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. (2021): 133 - 139. 10.4274/tnd.2021.50329 |
| MLA | Sacmacı Hikmet,AKTÜRK TÜLİN,TANIK NERMİN The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. , 2021, ss.133 - 139. 10.4274/tnd.2021.50329 |
| AMA | Sacmacı H,AKTÜRK T,TANIK N The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. . 2021; 133 - 139. 10.4274/tnd.2021.50329 |
| Vancouver | Sacmacı H,AKTÜRK T,TANIK N The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. . 2021; 133 - 139. 10.4274/tnd.2021.50329 |
| IEEE | Sacmacı H,AKTÜRK T,TANIK N "The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis." , ss.133 - 139, 2021. 10.4274/tnd.2021.50329 |
| ISNAD | Sacmacı, Hikmet vd. "The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis". (2021), 133-139. https://doi.org/10.4274/tnd.2021.50329 |
| APA | Sacmacı H, AKTÜRK T, TANIK N (2021). The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. Türk Nöroloji Dergisi, 27(2), 133 - 139. 10.4274/tnd.2021.50329 |
| Chicago | Sacmacı Hikmet,AKTÜRK TÜLİN,TANIK NERMİN The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. Türk Nöroloji Dergisi 27, no.2 (2021): 133 - 139. 10.4274/tnd.2021.50329 |
| MLA | Sacmacı Hikmet,AKTÜRK TÜLİN,TANIK NERMİN The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. Türk Nöroloji Dergisi, vol.27, no.2, 2021, ss.133 - 139. 10.4274/tnd.2021.50329 |
| AMA | Sacmacı H,AKTÜRK T,TANIK N The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. Türk Nöroloji Dergisi. 2021; 27(2): 133 - 139. 10.4274/tnd.2021.50329 |
| Vancouver | Sacmacı H,AKTÜRK T,TANIK N The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis. Türk Nöroloji Dergisi. 2021; 27(2): 133 - 139. 10.4274/tnd.2021.50329 |
| IEEE | Sacmacı H,AKTÜRK T,TANIK N "The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis." Türk Nöroloji Dergisi, 27, ss.133 - 139, 2021. 10.4274/tnd.2021.50329 |
| ISNAD | Sacmacı, Hikmet vd. "The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis". Türk Nöroloji Dergisi 27/2 (2021), 133-139. https://doi.org/10.4274/tnd.2021.50329 |
